American Brain Foundation’s Cure One, Cure Many Award in Lewy Body Dementia Grant

American Brain Foundation’s Cure One, Cure Many Award in Lewy Body Dementia Grant

Status: ACTIVE
Funder: American Brain Foundation
Amount: Up to US $2,000,000
Last Updated: June 18, 2025

Summary

The American Brain Foundation's Cure One, Cure Many Award in Lewy Body Dementia focuses on advancing research for this underdiagnosed condition. With LBD being the second most common progressive dementia, the foundation seeks innovative applications to discover and validate biomarkers. A grant of up to $2 million over three years is available, encouraging collaboration among diverse research teams to improve diagnosis and treatment options, ultimately aiming for breakthroughs that benefit many.

Overview

Since 1992, the American Brain Foundation (ABF) has been investing in research to defeat brain diseases and disorders. We are a national foundation for the brain dedicated to the relentless pursuit of improved prevention, treatment, and cures for brain diseases and disorders. We unite donors and researchers to improve the lives of those living with brain disease and their loved ones. We invest in research of the whole brain and all neurologic disorders knowing they are interconnected. This holistic, innovative approach allows us to build bridges between diseases and break new ground in research and application. Utilizing a whole-brain approach gives us an edge in understanding and combating brain disease. We understand that when we cure one brain disease, we will cure many. Hence our vision: Life without brain disease. Our founder and research partner is the American Academy of Neurology. American Brain Foundation’s Cure One, Cure Many Award in Lewy Body Dementia Lewy body dementia (LBD) is the second most common progressive dementia after Alzheimer’s disease and affects millions of individuals worldwide. When an individual presents with cognitive impairment, however, there are virtually no tools available to enable a clinician to make an accurate diagnosis of LBD. The lack of validated biomarkers for LBD contributes to delayed diagnosis and misdiagnosis, and thus potentially exposes individuals affected by LBD to inappropriate medication use and results in the failure to treat LBD-specific manifestations. The absence of biomarkers also impedes pertinent clinical and translational research, including drug and biomarker discovery efforts. In collaboration with the American Academy of Neurology (AAN), Alzheimer’s Association, and the Michael J. Fox Foundation for Parkinson’s Research, the 2025 Cure One, Cure Many Award in Lewy Body Dementia now seeks applications aimed for discovery, validation, and acceleration of LBD-related biomarkers. The ABF intends to award a single grant of up to US $2 million for a budget period of up to 3 years. Academic and nonprofit institutions are allowed to allocate up to 15% of the total award amount to indirect costs.

Eligibility

You can learn more about this opportunity by visiting the funder's website. Applications may be submitted by basic, translational, or clinical investigators from:U.S. and international public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government; andU.S. and international biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities.Past awardees are eligible to apply for this funding.